<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299779</url>
  </required_header>
  <id_info>
    <org_study_id>#10C.29</org_study_id>
    <nct_id>NCT01299779</nct_id>
  </id_info>
  <brief_title>Incidence of Hyponatremia in PEG-SD Compared to PEG-ELS</brief_title>
  <official_title>The Incidence of Hyponatremia With Two Commonly Prescribed Purgatives for Colonoscopy-Polyethylene Glycol 3350 With a Sports Drink (PEG-SD) Compared to Polyethylene Glycol 3350 With Electrolyte Solution (PEG-ELS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To compare the incidence of peri-colonoscopy hyponatremia associated with PEG 3350
      + sports drink (PEG-SD) versus PEG 3350-electrolyte solution + sodium sulfate + sodium
      ascorbate and ascorbic acid (PEG-ELS).

      Hypothesis: As compared to PEG-SD, hyponatremia occurs significantly less often with PEG-ELS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Looking at the Incidence of Hyponatremia With Two Commonly Prescribed Purgatives for
      Colonoscopy-Polyethylene Glycol 3350 With a Sports Drink (PEG-SD) Compared to Polyethylene
      Glycol 3350 With Electrolyte Solution (PEG-ELS)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of hyponatremia in the peri-colonoscopy period</measure>
    <time_frame>blood drawn 30 minutes post colonoscopy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of serum electrolytes levels outside the normal range for</measure>
    <time_frame>blood drawn 30 minutes post colonoscopy</time_frame>
    <description>Sodium, chloride, potassium, calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline for serum electrolytes</measure>
    <time_frame>blood drawn 30 minutes post colonoscopy</time_frame>
    <description>Sodium, chloride, potassium, calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function from baseline</measure>
    <time_frame>blood drawn pre colonoscopy and 30 minutes post colonoscopy</time_frame>
    <description>Creatinine, calculated GFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the following from baseline a. Serum vasopressin b. Serum osmolality c. Urine electrolytes and osmolality</measure>
    <time_frame>blood drawn pre colonoscopy and 30 minutes post colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cortisol and TSH levels for only patients who develop hyponatremia</measure>
    <time_frame>blood drawn 30 minutes post colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic/volume changes at baseline and immediately prior to colonoscopy</measure>
    <time_frame>hemodynamic measurments taken pre and post colonoscopy</time_frame>
    <description>Weight
Blood pressure supine and upright - systolic, diastolic
Pulse supine and upright
Development of orthostatic change: yes/no
Development of orthostatic symptoms - light-headed, dizzy, diaphoretic, etc.: yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events - Incidence and severity using 10-point Likert scale</measure>
    <time_frame>1 hour post colonoscopy assessment</time_frame>
    <description>GI - nausea, vomiting, abdominal pain, bloating
Light headedness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prep Completion: &lt;90% vs. &gt; 90%</measure>
    <time_frame>one time assessment pre colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indication for colonoscopy: Screen/Surveillance vs. Symptom</measure>
    <time_frame>one time assessment pre colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of independent risk factors for hyponatremia</measure>
    <time_frame>one time assessment pre colonoscopy</time_frame>
    <description>Age
Sex
Race
Medications
Medical history
BMI
Anxiety - Beck scale
Fluid intake for 24 hours prior to colonoscopy (not including the prep or fluids required to accompany the prep); patients will be shown a liter container to assist with their estimate.
i. Less than 3 Liters ii. 3-5 liters iii. More than 5 liters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>endoscopist will evaluate during colonoscopy</time_frame>
    <description>Whole colon prep: adequate (excellent/good) vs. inadequate (fair/poor)
Cecal or small bowel intubation - Yes/No</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>PEG-ELS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-SD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-SD</intervention_name>
    <description>PEG-SD
Bisacodyl: two 5-mg tablets at 3 pm day prior
1L sports drink* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior
1L SD* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy
Same flavor, non-red GatoradeÂ® for all patients.</description>
    <arm_group_label>PEG-SD</arm_group_label>
    <other_name>Miralax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-ELS</intervention_name>
    <description>1L + 500 cc clear liquids at 6 pm night prior
1L + 500 cc clear liquids starting 4 hours prior to colonoscopy</description>
    <arm_group_label>PEG-ELS</arm_group_label>
    <other_name>MoviPrep</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults age 18 years or older scheduled for elective outpatient colonoscopy: 8am -
             noon.

        Exclusion Criteria:

          -  Unable or unwilling to consent

          -  Pregnant

          -  Breast feeding

          -  Significant psychiatric illness

             -&gt; 50% colon resection

          -  Bowel obstruction

          -  History of hyponatremia (Serum sodium &lt;135 mmol/L)

          -  End stage renal disease on dialysis

          -  History of chronic kidney disease (other than kidney stones)

          -  Decompensated cirrhosis, including:

               -  History of bleeding due to portal hypertension (varices, gastropathy, etc) within
                  3 months

          -  Hepatic encephalopathy (not controlled with medications) within 3 months

          -  Clinical presence of ascites

          -  Active cardiac disease

          -  Recent myocardial infarction (&lt;4weeks)

          -  Unstable angina

          -  Congestive heart failure NYHA Functional Class Stage III or IV

          -  Stage III: Marked limitation of activity. Less than ordinary activity (e.g. walking
             short distances, 20-100 m) causes fatigue, palpitations, dyspnea. Comfortable at rest.

          -  Stage IV: Severe limitations. Experiences symptoms even while at rest. Mostly bedbound
             patients.

        Exclusion Criteria (post-enrollment), from baseline labs:

          -  Serum creatinine &gt; 1.5 mg/dL

          -  Serum potassium &lt; 3.3 or &gt; 5.5 mmol/L

          -  Serum sodium &lt; 135 mmol/L or &gt;150 mmol/L

          -  Serum calcium &lt; 8.0 or &gt; 11.0 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kastenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyponatremia</keyword>
  <keyword>PEG-SD</keyword>
  <keyword>PEG-ELS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

